Friday, 16 October 2026European Markets

EKOPAK Stock Went Up By Over 15% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of EKOPAK (BEL 20: EKOP.BR) rose by a staggering 15.61% in 5 sessions from €17.3 to €20.00 at 17:09 EST on Tuesday, following the last session's downward trend. BEL 20 is jumping 0.59% to €3,527.83, after two consecutive sessions in a row of gains.

About EKOPAK

Ekopak NV designs, builds, finances, and operates industrial water processing solutions in Belgium, France, and internationally. It operates in two segments, Water-as-a-Service (WaaS) and Non-WaaS. The company offers cooling and feed, boiler, and process water treatment; corrosion control; ultra-filtration; legionella prevention; and disinfection. The company also supplies chemicals for internal water treatment for protection against corrosion of and deposits on steam boilers, hot water and heating circuits, drinking water circuits, and cooling towers and circuits. In addition, it designs, constructs, and optimizes various water treatment equipment, which include dosing stations, spraying systems, disinfection units, water softeners, decarbonation and demineralization units, reverse osmosis units, filtration units, iron and manganese removal units, activated carbon filtration units, and physico-chemical and biological wastewater stations, as well as online monitoring, and disinfection and acidity units. It serves to the chemical, food, medical, textile, and other industries. Ekopak NV was incorporated in 1997 and is headquartered in Tielt, Belgium.

Earnings Per Share

As for profitability, EKOPAK has a trailing twelve months EPS of €-0.15.

Volume

Today's last reported volume for EKOPAK is 6230 which is 56.2% above its average volume of 3352.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EKOPAK's stock is considered to be oversold (<=20).

Volatility

EKOPAK's last week, last month's, and last quarter's current intraday variation average was 5.01%, 0.83%, and 1.53%.

EKOPAK's highest amplitude of average volatility was 5.01% (last week), 2.07% (last month), and 1.53% (last quarter).

More news about EKOPAK (EKOP.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com